Marché du traitement du cancer gastrique en Amérique centrale – Tendances et prévisions de l’industrie jusqu’en 2029

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché du traitement du cancer gastrique en Amérique centrale – Tendances et prévisions de l’industrie jusqu’en 2029

  • Pharmaceutical
  • Publish Reports
  • Mar 2022
  • Country Level
  • 350 Pages
  • Nombre de tableaux : 64
  • Nombre de figures : 48

>Marché du traitement du cancer gastrique en Amérique centrale , par type (adénocarcinome, tumeur stromale gastro-intestinale, tumeur carcinoïde, lymphome et autres), stades (stade III, stade II, stade IV, stade I et autres), traitement ( chimiothérapie , thérapie ciblée, inhibiteurs du point de contrôle immunitaire et autres), voie d'administration (parentérale, orale et autres), utilisateur final (hôpitaux, cliniques spécialisées, instituts de recherche et universitaires et autres), canal de distribution (pharmacie hospitalière, pharmacie de détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2029.

Marché du traitement du cancer gastrique en Amérique centrale

Analyse et perspectives du marché du traitement du cancer gastrique en Amérique centrale

L'adénocarcinome gastrique est le quatrième type de cancer le plus courant et la deuxième cause de décès par cancer dans le monde. Le cancer de l'estomac est une croissance anormale de cellules qui commence dans l'estomac. Le cancer de l'estomac, également appelé cancer gastrique , peut affecter n'importe quelle partie de l'estomac. Dans la plupart des pays du monde, les cancers de l'estomac se forment dans la partie principale de l'estomac (corps de l'estomac). Mais aux États-Unis, le cancer de l'estomac est plus susceptible d'affecter la zone où l'œsophage rencontre l'estomac. Cette zone est appelée jonction gastro-œsophagienne.

Cancer gastrique en Amérique centrale

L'augmentation de l'incidence des tumeurs gastro-intestinales avec le rythme croissant de la population gériatrique démontre l'escalade du nombre de traitements contre le cancer gastrique. Compte tenu de cela, on estime que la croissance de la population gériatrique est un facteur moteur majeur de la croissance du marché.

Le traitement du cancer gastrique est symptomatique et vise à réduire la progression de la maladie. Data Bridge Market Research analyse que le traitement du cancer gastrique héréditaire connaîtra un TCAC de 7,2 % au cours de la période de prévision de 2022 à 2029.

Rapport métrique

Détails

Période de prévision

2022 à 2029

Année de base

2021

Années historiques

2020 (personnalisable de 2019 à 2014)

Unités quantitatives

Chiffre d'affaires en millions USD, prix en USD

Segments couverts

Par type (adénocarcinome, tumeur stromale gastro-intestinale, tumeur carcinoïde, lymphome et autres), stades (stade I, stade II, stade III, stade IV et autres), traitement (chimiothérapie, thérapie ciblée, inhibiteurs du point de contrôle immunitaire et autres), voie d'administration (orale, parentérale et autres), utilisateur final (hôpitaux, cliniques spécialisées, instituts de recherche et universitaires et autres), canal de distribution (pharmacie hospitalière, pharmacie de détail et autres)

Pays couverts

Costa Rica, Guatemala, Panama, République dominicaine et reste de l'Amérique centrale

Acteurs du marché couverts

Hoffmann-La Roche Ltd., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Laboratorio Varifarma SA, Seven pharma, Janssen Global Services, LLC (une filiale de Johnson & Johnson Services, Inc.) et Sanofi, entre autres

Dynamique du marché du traitement du cancer gastrique

Conducteurs

  • Increase in Incidence of Gastrointestinal Tumours, Lymphoma, and Adenocarcinoma

The increased incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma is increasing the demand for the early detection and diagnosis via utilizing the latest technology, thereby propelling the growth of the Central America gastric cancer treatment market.

  • Rise in Alcohol Consumption and Surge in Smoking

The combined use of cigarettes and alcohol poses health concerns and severe public health issue that collectively lead to gastric cancer. A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing that aero-digestive tract to cancer-causing chemicals.

Also, the high incidence of obesity in these countries is expected to drive the growth of Central America gastric cancer treatment market.

Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, recent advancements in gastric cancer treatment, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the gastric cancer treatment market.

Cancer gastrique en Amérique centrale

Opportunities

  • Healthcare Expenditure of Central American Countries

Moreover, the increase in awareness and treatment-seeking rate and emerging reimbursement policies for the treatment will boost new opportunities for the market's growth rate.

Also, the increasing drug approvals will provide beneficial opportunities for the gastric cancer treatment market in the forecast period of 2022-2029. Also, the partnership and agreement by major players will escalate the growth rate of the gastric cancer treatment market in the future.

Restraints/Challenges

However, the costs associated with other medical care and interventions (such as surgical interventions and radiotherapy) and supportive care (such as anti-emetics and hematopoietic growth factors) would make overall care even more unaffordable. Even with insurance coverage, patients living with cancer in many countries have reported financial stress, to the extent that they may lower the treatment dose, partially fill prescriptions, or even forego treatment altogether.

This gastric cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Gastric Cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Gastric cancer disease is the 5th most commonly diagnosed cancer in the world, and the 7th most prevalent. Gastric cancer is more prevalent in males. In developed countries, gastric cancer is 2.2 times more likely to be diagnosed in males than females. In developing countries, this ratio is 1.83. In 5 countries worldwide, gastric cancer has the highest incidence among all cancers for males.

Most cancers of the stomach (about 90% to 95%) are adenocarcinomas. These cancers develop from the gland cells in the innermost lining of the stomach (the mucosa). Stomach cancer mostly affects older people. The average age of people when they are diagnosed is 68. About 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. The lifetime risk of developing stomach cancer is higher in men (about 1 in 96) than in women (about 1 in 152). But each person's risk can be affected by many other factors

The gastric cancer treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Post COVID-19 Impact on Gastric Cancer Treatment Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

  • In March 2021, Amgen and Five Prime Therapeutics, a clinical-stage biotechnology company that is focused on developing immuno-oncology and targeted cancer therapies, announced an agreement under which Amgen will acquire Five Prime Therapeutics. The acquisition will also include Bemarituzumab, A Phase 3 program for gastric cancer

Central America Gastric Cancer Treatment Market Scope

Central America gastric cancer treatment market is categorized into six notable segments, which are based on type, stage, treatment, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

  • Adenocarcinoma
  • Lymphoma
  • Gastrointestinal stromal tumor
  • Carcinoid tumor
  • Others

On the basis of type, the market is segmented into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and others.

Stage

  • Stage I
  • Stage II
  • Stage III
  • Stage IV
  • Others

On the basis of stage, the market is segmented into stage I, stage II, stage III, stage IV, and others.

Treatment

  • Chemotherapy
  • Targeted Therapy
  • Immune Checkpoint Inhibitors
  • Others

On the basis of treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others.

Route of Administration

  • Oral
  • Parenteral

On the basis of route of administration, the market is segmented into oral and parenteral.

End User

  • Hospitals
  • Specialty Clinics
  • Research and Academic Institutes
  • Others

On the basis of end-users, the Central America gastric cancer treatment market is segmented into hospitals, specialty clinics, research and academic institutes and others.

Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Others

Central America gastric cancer treatment market is also segmented on the basis of distribution channel into retail pharmacy, hospital pharmacy and others.

Pipeline Analysis

Cancer gastrique en Amérique centrale

The pipeline analysis of drugs includes various pipeline therapies such as Zolbetuximab (IMAB362) plus mFOLFOX6, Nivolumab and Ipilimumab, Pembrolizumab (MK-3745) + Cisplatin, Regorafenib (Stivarga, BAY73-4506), lapatinib, NCT03653507, Durvalumab or Placebo and FLOT Chemotherapy. Astellas Pharma Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Bayer AG, Novartis AG are involved in the development of potential drugs for the improvement of treatment of gastric cancer.

Gastric Cancer Treatment Market Regional Analysis/Insights

The gastric cancer treatment market is analysed and market size insights and trends are provided by country, type, stages, treatment, route of administration, end-user and distribution channel as referenced above.

The countries covered in the gastric cancer treatment market report are Costa Rica, Guatemala, Panama, Dominican Republic and rest of Central America.

Le Costa Rica domine le marché du traitement du cancer gastrique en termes de part de marché et de chiffre d'affaires et continuera à accroître sa domination au cours de la période de prévision. Cela est dû à la présence d'acteurs clés majeurs et à une infrastructure de soins de santé bien développée dans ce pays.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché qui ont un impact sur les tendances actuelles et futures du marché. Les points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation, sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la forte concurrence des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché du traitement du cancer gastrique en Amérique centrale

Le paysage concurrentiel du marché du traitement du cancer gastrique fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises vers le traitement du cancer gastrique.

Certaines des principales entreprises opérant sur le marché du traitement du cancer gastrique en Amérique centrale sont F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Laboratorio Varifarma SA, Seven pharma, Janssen Global Services, LLC (une filiale de Johnson & Johnson Services, Inc.) et Sanofi, entre autres.

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport aux régions et la part des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

4.3 INNOVATIVE TREATMENT VS CHEMOTHERAPY

4.3.1 TARGETED THERAPIES

4.3.2 CHEMOTHERAPY

4.3.3 CONCLUSION

4.3.4 PRIMARY LINE OF TREATMENT OF GASTRIC CANCER

5 EPIDERMOLOGY

6 PIPELINE ANALYSIS FOR CHILE GASTRIC CANCER TREATMENT MARKET

7 REGULATIONS OF CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET

7.1 COSTA RICA

7.2 GUATEMALA

7.3 PANAMA

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA

8.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING

8.1.3 HIGH INCIDENCE OF OBESITY

8.1.4 RECENT ADVANCEMENT IN GASTRIC CANCER TREATMENT

8.2 RESTRAINTS

8.2.1 HIGH COST OF TESTING AND MEDICATIONS

8.2.2 ADVERSE SIDE-EFFECTS OF GASTRIC CANCER TREATMENT

8.3 OPPORTUNITIES

8.3.1 HEALTHCARE EXPENDITURE IN CENTRAL AMERICAN COUNTRIES

8.3.2 INCREASING DRUG APPROVALS

8.3.3 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS

8.3.4 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT

8.4 CHALLENGES

8.4.1 OLD AGE CHALLENGES

8.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES

9 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY TYPE

9.1 OVERVIEW

9.2 ADENOCARCINOMA

9.3 GASTROINTESTINAL STROMAL TUMOR

9.4 CARCINOID TUMOR

9.5 LYMPHOMA

9.6 OTHERS

10 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY STAGES

10.1 OVERVIEW

10.2 STAGE III

10.3 STAGE II

10.4 STAGE IV

10.5 STAGE I

10.6 OTHERS

11 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT

11.1 OVERVIEW

11.2 CHEMOTHERAPY

11.2.1 FLUOROURACIL

11.2.2 OXALIPLATIN

11.2.3 CISPLATIN

11.2.4 DOCETAXEL

11.2.5 PACLITAXEL

11.2.6 IRINOTECAN

11.2.7 CAPECITABINE

11.2.8 CARBOPLATIN

11.2.9 EPIRUBICIN

11.2.10 OTHERS

11.3 TARGETED THERAPY

11.3.1 MONOCLONAL ANTIBODY THERAPY

11.3.1.1 TRASTUZUMAB (HERCEPTIN)

11.3.1.2 RAMUCIRUMAB

11.3.2 MULTIKINASE INHIBITORS

11.3.2.1 SUNITINIB

11.3.2.2 REGORAFENIB

11.4 IMMUNE CHECKPOINT INHIBITORS

11.5 OTHERS

12 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 PARENTERAL

12.2.1 INTRAVENOUS

12.2.2 SUBCUTANEOUS

12.2.3 OTHERS

12.3 ORAL

12.3.1 TABLET

12.3.2 CAPSULE

12.3.3 OTHERS

12.4 OTHERS

13 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 SPECIALITY CLINICS

13.4 RESEARCH & ACADEMIC INSTITUTES

13.5 OTHERS

14 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 RETAIL PHARMACY

14.4 OTHERS

15 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY COUNTRY

15.1 CENTRAL AMERICA

15.1.1 COSTA RICA

15.1.2 PANAMA

15.1.3 GUATEMALA

15.1.4 DOMINICAN REPUBLIC

15.1.5 REST OF CENTRAL AMERICA

16 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: CENTRAL AMERICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 MERCK & CO., INC

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENTS

18.1.4.1 PRODUCT APPROVAL

18.1.4.2 EVENTS

18.2 F.HOFFMANN-LA ROCHE AG

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 PRODUCT PORTFOLIO

18.2.4 RECENT DEVELOPMENT

18.2.4.1 AGREEMENT

18.3 ELI LILLY AND COMPANY

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 PRODUCT PORTFOLIO

18.3.4 RECENT DEVELOPMENT

18.3.4.1 APPROVAL

18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 PRODUCT PORTFOLIO

18.4.4 RECENT DEVELOPMENT

18.4.4.1 COLLABORATION

18.5 BRISTOL-MYERS SQUIBB COMPANY

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.5.4.1 PRODUCT APPROVAL

18.6 BAYER AG

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.6.4.1 COLLABORATION

18.7 SEVEN PHARMA

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENT

18.8 JANSSEN GLOBAL SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENT

18.9 ASTRAZENECA

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENT

18.9.4.1 PRODUCT APPROVAL

18.1 LABORATORIO VARIFARMA SA

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.10.3.1 EXPANSION

18.11 NOVARTIS AG

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.11.4.1 PRODUCT LAUNCH

18.12 PFIZER INC.

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.12.4.1 MERGER

18.12.4.2 COLLABORATION

18.13 SANOFI

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENT

18.13.4.1 ACQUISITION

19 QUESTIONNAIRE

20 RELATED REPORTS

Liste des tableaux

T, BY STAGES, 2020-2029 (USD MILLION)

TABLE 5 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 6 CENTRAL AMERICA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 7 CENTRAL AMERICA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 8 CENTRAL AMERICA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 9 CENTRAL AMERICA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 10 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 11 CENTRAL AMERICA PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 12 CENTRAL AMERICA ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 13 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 14 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 15 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 16 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 18 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 19 COSTA RICA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 COSTA RICA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 COSTA RICA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 COSTA RICA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 24 COSTA RICA PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 25 COSTA RICA ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 26 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 27 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 28 PANAMA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 29 PANAMA GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 30 PANAMA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 PANAMA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 32 PANAMA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 33 PANAMA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 34 PANAMA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 PANAMA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 36 PANAMA PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 37 PANAMA ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 38 PANAMA GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 39 PANAMA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 40 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 42 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 GUATEMALA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 44 GUATEMALA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 45 GUATEMALA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 46 GUATEMALA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 48 GUATEMALA PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 49 GUATEMALA ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 50 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 51 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 52 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 54 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 55 DOMINICAN REPUBLIC CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 56 DOMINICAN REPUBLIC TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 57 DOMINICAN REPUBLIC MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 58 DOMINICAN REPUBLIC MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 59 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 60 DOMINICAN REPUBLIC PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 61 DOMINICAN REPUBLIC ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 62 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 63 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 64 REST OF CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

Liste des figures

FIGURE 1 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 2 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 8 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: END USER OVERAGE GRID

FIGURE 11 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 12 INCREASING IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA AND ADENOCARCINOMA AND HIGH PREVALENCE OF OBESITY ARE EXPECTED TO DRIVE THE CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 ADENOCARCINOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET IN 2022 & 2029

FIGURE 14 CONDITIONALLY RECOMMENDED REGIME

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET

FIGURE 16 PER CAPITA EXPENSE AND HEALTHCARE EXPEDITURE (% OF GDP) OF COSTA RICA

FIGURE 17 PER CAPITA EXPENSE AND CURRENT HEALTHCARE EXPEDITURE (% OF GDP) OF GUATEMALA

FIGURE 18 PER CAPITA EXPENSE AND CURRENT HEALTHCARE EXPEDITURE (% OF GDP) OF GUATEMALA

FIGURE 19 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2021

FIGURE 20 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 21 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 22 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2020-2029, LIFELINE CURVE

FIGURE 23 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2021

FIGURE 24 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2022-2029 (USD MILLION)

FIGURE 25 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY STAGES, CAGR (2022-2029)

FIGURE 26 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 27 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 28 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 29 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 30 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 31 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 32 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 33 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 34 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029, LIFELINE CURVE

FIGURE 35 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY END USER 2021

FIGURE 36 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 37 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 38 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY END USER, 2020-2029, LIFELINE CURVE

FIGURE 39 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 40 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 41 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 42 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 44 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 45 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 46 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 47 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE (2022-2029)

FIGURE 48 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The Central America Gastric Cancer Treatment Market will grow at a CAGR of 7.2% during the forecast period of 2022 to 2029.
The significant factors flourishing the growth of the Central America Gastric Cancer Treatment Market are Increase in Incidence of Gastrointestinal Tumours, Lymphoma, and Adenocarcinoma, and Rise in Alcohol Consumption and Surge in Smoking.
The major players operating in the Central America Gastric Cancer Treatment Market are Hoffmann-La Roche Ltd., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Laboratorio Varifarma SA, Seven pharma, Janssen Global Services, LLC (A subsidiary of Johnson & Johnson Services, Inc.) and Sanofi among others.
The major Countries Covered in the Central America Gastric Cancer Treatment Market are Costa Rica, Guatemala, Panama, Dominican Republic and Rest of Central America.